Compare CSPI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | SCLX |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 139.3M |
| IPO Year | 1987 | N/A |
| Metric | CSPI | SCLX |
|---|---|---|
| Price | $13.01 | $14.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 71.9K |
| Earning Date | 12-16-2025 | 11-14-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,730,000.00 | $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $9.65 | $3.60 |
| 52 Week High | $21.95 | $34.27 |
| Indicator | CSPI | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 36.11 |
| Support Level | $12.74 | $12.87 |
| Resistance Level | $13.78 | $20.62 |
| Average True Range (ATR) | 0.96 | 1.04 |
| MACD | -0.10 | -0.37 |
| Stochastic Oscillator | 30.79 | 18.54 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.